Non-cardiac surgery and antiplatelet therapy following coronary artery stenting.
Coronary artery stenting is increasingly used as a treatment for coronary artery disease. A period of antiplatelet therapy is mandatory following coronary stenting, in order to minimise the risk of stent thrombosis. About 5% of patients who undergo coronary stenting will require non-cardiac surgery within 12 months, and the management of antiplatelet therapy in this setting is complex, requiring a balance between the risks of both operative haemorrhage and stent thrombosis. The available evidence to guide decision-making in the management of antiplatelet therapy in this setting is reviewed.
Luckie
M
M
Manchester Heart Centre, Manchester Royal Infirmary, Manchester, UK.
Khattar
R S
RS
Fraser
D
D
D016063:Blood Loss, Surgical; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D006801:Humans; D009204:Myocardial Revascularization / Q000379:methods; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D024162:Second-Look Surgery; D015607:Stents
D010975:Platelet Aggregation Inhibitors